Teleflex(TFX) - 2025 Q4 - Earnings Call Transcript

Financial Data and Key Metrics Changes - For 2025, adjusted earnings per share (EPS) was $6.98, representing an 8.7% increase year-over-year, primarily due to higher revenue and adjusted operating income [16][17] - Adjusted gross margin for 2025 was 63.7%, a decrease of 200 basis points year-over-year, attributed to tariffs, the acquisition of Vascular Intervention, and increased logistics costs [15][16] - Adjusted operating margin for 2025 was 22.7%, reflecting a 230 basis point decrease year-over-year due to gross margin pressure and higher operating expenses [15][16] Business Line Data and Key Metrics Changes - Vascular revenue increased 2.4% year-over-year to $472.7 million, driven by growth in Central Access, hemostatic, and atomization products [14] - Interventional revenue was $427.5 million, an increase of 8.1%, supported by a broad portfolio [14] - Surgical revenue was $219.3 million, reflecting a 3.2% increase, influenced by volume-based procurement in China [14][15] Market Data and Key Metrics Changes - Continuing operations delivered 4.7% pro forma adjusted constant currency revenue growth in the second half of 2025, establishing a solid foundation for future growth [28][22] - Pro forma adjusted constant currency revenue growth for 2026 is expected to be in the range of 4.5%-5.5% [22] Company Strategy and Development Direction - The company is undergoing a transformation to optimize its portfolio and focus on high-growth areas, with plans to return significant capital to shareholders through a $1 billion share repurchase program [5][27] - The strategic divestitures of Acute Care, Interventional Urology, and OEM businesses are expected to close in the second half of 2026, with net proceeds of approximately $1.8 billion to be used for share repurchases and debt repayment [7][20] - R&D investment for RemainCo is expected to represent approximately 8% of sales, up from 5% historically, indicating a focus on product innovation [8][71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving mid-single-digit revenue growth and significant increases in adjusted EPS in 2027 and beyond, driven by cost mitigation and capital deployment actions [30][50] - The company is actively managing stranded costs of approximately $90 million associated with the divestitures, with plans to offset these through transition service agreements and restructuring initiatives [9][24] Other Important Information - The company is currently in a CEO search process, focusing on candidates with experience in high-growth, mid-size organizations operating in global healthcare settings [51] - A restructuring plan has been approved to eliminate stranded costs and streamline operations, targeting approximately $50 million in annual pre-tax savings [24][30] Q&A Session Summary Question: Use of proceeds from divestitures - The company plans to allocate $1 billion for share repurchases and approximately $800 million for debt repayment, primarily targeting the deferred draw revolver from the Bison acquisition [33] Question: Restructuring savings impact on EPS guidance - Some restructuring savings are included in the EPS guidance range of $6.25-$6.55 for 2026, with additional savings expected post-2026 [34] Question: Confidence in revenue growth for 2026 - The company is confident in its growth trajectory due to sales synergies and easier comparisons in the second half of 2026, despite some ongoing volume-based procurement impacts [81] Question: BIOTRONIK integration update - The integration of the BIOTRONIK sales force is progressing well, with no significant talent losses and opportunities for revenue synergies identified [69][70] Question: Future margin expansion post-transition service agreements - The company aims to mitigate stranded costs and leverage operational efficiencies to improve margins, with expectations for continued growth in earnings and margins beyond 2026 [75][76]